Litigations for HIV Related Complications

Chapter
Part of the Emerging Infectious Diseases of the 21st Century book series (EIDC)

Abstract

In 1992, a 27-year-old male with same sex exposure requested human immuno-deficiency virus (HIV) testing anonymously at a walk-in clinic. He was advised that the test (HIV serology) was positive and he requested a repeat test (anonymously) 1 month later, which was also reported as being positive. About 2 years later, he was assessed by a general practitioner for symptoms of depression and continued medical care. At that time, investigations revealed a CD4 T-cell count of about 700 cells/uL. Sometime in 1996 a repeat blood test revealed a CD4 cell count just <500 cells/uL. No consultation to an infectious diseases specialist or HIV clinic was made. The GP(general practitioner) then initiated a regimen consisting of didanosine, lamivudine, and saquinavir for HIV infection. At that time, testing for HIV viral load was not generally available to the medical community, but became procurable in 1997. Initially, the patient tolerated the regimen well and over the next 3 years his CD4 cell count was maintained above 600–700 cells/uL and the HIV viral load remained undetectable (<50 copies). However, the patient started to show morphologic changes of moderate facial and peripheral lipoatrophy, developed mild sensory peripheral neuropathy, and increased liver enzymes attributable to fatty liver, and elevations of the fasting serum glucose. In the summer of 2000, although the CD4 cell count remained stable, the HIV viral load was reported as being over 7,000 copies/uL. At this time, the patient was referred to a university hospital HIV clinic.

Keywords

Hepatitis Tuberculosis Retina Cocaine Sarcoma 

References

  1. 1.
    Bylund DJ, Ziegner UHM, Hooper DG (1992). Review of testing for human immunodeficiency virus. Lab Immunol II, 12:305–333.Google Scholar
  2. 2.
    Marlink RG, Allen JS, McLane MF, Essex M, Anderson KC, Groopman JE (1986). Low sensitivity of ELISA testing in early HIV infection. N Engl J Med 315:1549.PubMedGoogle Scholar
  3. 3.
    Horsburgh Jr CR, Ou LY, Jason J, Holmberg SD, Longini IM Jr, Schable CA, Mayer KH, Lifson AR, Schochetman, G, Ward W, Rutherford GW, Evatt BL, Seage GR III, Jaffe HW (1989). Duration of human immunodeficiency virus infection before detection of antibody. Lancet 2:637–639.PubMedCrossRefGoogle Scholar
  4. 4.
    Burke DS, Brundage JF, Redfield RR, Damato, JJ, Schable CA, Putman P, Visintine R, Kim HI (1988). Measurement of the false positive rate in a screening program for human immunodeficiency virus infection. N Engl J Med 319:961–964.PubMedCrossRefGoogle Scholar
  5. 5.
    Lifson AR, Stanley M, Pane J, O’Malley PM, Wilber JC, Stanley A, Jeffrey B, Rutherford GW, Sohmer PR (1990). Detection of human immunodeficiency virus DNA using polymerase chain reaction in a well-characterized group of homosexual and bisexual men. J Infect Dis 161:436–439.PubMedCrossRefGoogle Scholar
  6. 6.
    Horsburgh CR Jr, Ou CY, Jason J, Holmberg SD, Lifson AR, Ward JW, Seage CR, Mayer KH, Evatt BC (1990). Concordance of polymerase chain reaction with human immunodeficiency virus antibody detection. J Infect Dis 162:542–545.PubMedCrossRefGoogle Scholar
  7. 7.
    Letvin NL (2008). Immunology of HIV infection. IN (ed): Paul, WE. Fundamental Immunology, 6th Edition, Wolter Kluwer/Lippincott, Williams & Wilkins, Philadelphia, p1204–1232.Google Scholar
  8. 8.
    Kipps TJ (2006). Lymphocytes and lymphocytopenia. IN (eds): Licktman MA, Beutter E, Kipps TJ, Seligsohn U, Kaushansky K, Prchal JT. William’s Hematology, 7th Edition, Mc-Graw Hill Medical, New York, p1087–1097.Google Scholar
  9. 9.
    Zumwait RE, McFeeley PJ, Maito J (1987). Fraudulent AIDS. JAMA, 257:3231.CrossRefGoogle Scholar
  10. 10.
    Evans GA, Gill MJ, Gerhart S (1998). Factitious AIDS. N Engl J Med 319:1605–1606.Google Scholar
  11. 11.
    Zuger A, O’Dowd MA (1992). The baron has AIDS: a case of fictitious human immuno-deficiency virus infection and review. Clin Infect Dis 14:211–216.PubMedCrossRefGoogle Scholar
  12. 12.
    Milano MD, Barnowski C, Fiore T, Gormley J, Rich JD, Emgushove RT, Carpenter CC (2001). Factitious HIV syndrome in young women. AIDS Read 11:278–282.Google Scholar
  13. 13.
    Craven DE, Steger KA, La Chapelle R, Allan DM (1994). Factitious HIV infection: the importance of documenting infection. Ann Intern Med 121:763–766.PubMedGoogle Scholar
  14. 14.
    Churchill DR, De Cock KM, Miller RF (1994). Feigned HIV infection/AIDS: malingering and Munchausen’s syndrome. Genitourin Med 70: 314–316.PubMedGoogle Scholar
  15. 15.
    Niu MT, Stein DS, Schnittman SM (1993). Primary human immunodeficiency virus type I infection: review of pathogenesis and early treatment intervention in humans and animal retrovirus infection. J Infect Dis 168:1490–1501.PubMedCrossRefGoogle Scholar
  16. 16.
    Pedersen C, Lindhardt BO, Jensen BL, Lauritzen E, Gerstoft J, Dickmeis E, Gaub J, Scheibel E, Karlsmark T (1989). Clinical course of primary HIV infection. Br Med J 299:154–157.CrossRefGoogle Scholar
  17. 17.
    Mellors JW, Renaldo CR Jr, Gupta P, White RM, Todd J, Kingsley LA (1996). Prognosis in HIV infection predicted by the quantity of virus in plasma. Science 272:1167–1170.PubMedCrossRefGoogle Scholar
  18. 18.
    Stein DS, Korvick JA, Vermund SH (1992). CD4+ lymphocyte cell enumeration for prediction of clinical course of human immunodeficiency virus disease: J Infect Dis 165:352–263.PubMedCrossRefGoogle Scholar
  19. 19.
    Fauci AS, Pantaleo G, Stanley S, Weissman D (1996). Immunopathogenic mechanisms of HIV infection. Ann Intern Med 124:654–663.PubMedGoogle Scholar
  20. 20.
    Learmont JC, Geczy AF, Mills J, Ashton LJ, Raynes-Greennow CH, Garsia RJ, Dyer WB, McIntyre L, Oelrichs RB, Rhodes DI, Deacon NJ, Sullivan JS, For the Sydney Blood Bank Cohort Research Group (1999). Immunologic and virologic status after 14 to 18 years of infection with an attenuated strain of HIV-1. N Engl J Med 340:1715–1722.PubMedCrossRefGoogle Scholar
  21. 21.
    Kirchoff F, Greenough TC, Brettler DB, Sullivan JC, Desrosiers RC (1995). Brief report: absence of intact Nef sequence in a long-term survivor with non-progressive HIV-1 infection. N Engl J Med 332:228–232.CrossRefGoogle Scholar
  22. 22.
    Keet IPM, Tang J, Klein MR, LeBlanc S, Enger C, Rivers C, Apple RJ, Mann D, Goedert JJ, Miedema F, Kaslow RA (1999). Consistent associations of class I and II and transporter gene products with progression of human immunodeficiency virus type I infection in homosexual men. J Infect Dis 180:299–309.PubMedCrossRefGoogle Scholar
  23. 23.
    Levy JA (ed) (2007). Overall features of HIV pathogenesis prognosis for long term survival. IN: HIV and the Pathogenesis of AIDS, 3rd Edition, ASM Press, Washington DC, p317–361.Google Scholar
  24. 24.
    Hunt PW (2009). Natural control of HIV-1 replication and long-term non-progression: overlapping but distinct phenotypes. J Infect Dis 200:1636–1638.PubMedCrossRefGoogle Scholar
  25. 25.
    Dean M, Carrington M, Winkler C, Huttley GA, Smith MW, Allikmets R, Goedert JJ, Bachbinder SP, Vittinghoff E, Gomperts E, Donfield S, Vlahov D, Kaslow R, Saah A, Rinaldo C, Detels R, O’Brien SJ (1996). Genetic restriction of HIV-1 infection and progression to AIDS by a deletion allele of the CKR5 structural gene. Science 273:1856–1862.PubMedCrossRefGoogle Scholar
  26. 26.
    Webster A, Lee CA, Cook DG, Grundy JE, Emery VC, Kenoff PBA, Griffiths PD (1989). Cytomegalovirus infection and progression towards AIDS in hemophiliacs with human immunodeficiency virus infection. Lancet 11:63–66.CrossRefGoogle Scholar
  27. 27.
    Robain M, Bonfassa F, Hubert J, Persoz A, Burgard M, Meyer L (2001). Cytomegalovirus seroconversion as a cofactor for progression to AIDS. AIDS 15:251–256.PubMedCrossRefGoogle Scholar
  28. 28.
    Bartholomew C, Blattner W, Cleghorn F (1987). Progression to AIDS in homosexual men coinfected with HIV-1 and HTLV-1 in Trinidad. Lancet ii:1469.CrossRefGoogle Scholar
  29. 29.
    Page JB, Lai S, Chitwood DD, Klimas NG, Smith PC, Fletcher MA (1990). HTLV-I/II seropositivity and death from AIDS among HIV-I seropositive intravenous drug users. Lancet: 335:1439–1441.CrossRefGoogle Scholar
  30. 30.
    Wallis RS, Vjecha M, Amir-Tahmasseb M, Okwera F, Byekwaso S, Nyole S, Kabengera S, Mugererwa RD, Ellner JJ (1993). Influence of tuberculosis on human immunodeficiency virus (HIV-I): enhanced cytokine expression and elevated B2-microglobulin in HIV-I associated tuberculosis. J Infect Dis 167:43–48.PubMedCrossRefGoogle Scholar
  31. 31.
    Morris L, Martin DJ, Bredell H, Nyoka SN, Sack SL, Pendle S, Page-Shipp L, Karp CL, Sterling TR, Quinn TC, Chaisson RE (2003). Human immunodeficiency virus-I RNA levels and CD4 lymphocyte counts during treatment for active tuberculosis in South African patients. J Infect Dis 187:1967–1971.PubMedCrossRefGoogle Scholar
  32. 32.
    Vasan A, Renjiifo B, Hertzmark E, Chaplin B, Msamanga G, Essex M, Fawzi W, Hunter D (2006). Different rates of disease progression of HIV type I infection in Tanzania based on infecting subtype. Clin Infect Dis 42:843–852.PubMedCrossRefGoogle Scholar
  33. 33.
    Kanki PJ, Hamel DJ, Sankale JL, Hsieh CC, Thior I, Barin F, Woodcock SA, Grueye-Ndiaye A, Zhang L, Montano M, Siby T, Marlink R, Ndoye I, Essex ME, MBoup S (1999). Human immunodeficiency virus type I subtypes differ in disease progression. J Infect Dis 179:68–73.PubMedCrossRefGoogle Scholar
  34. 34.
    Sugar M, Lawreys L, Baeten JM, Richardson BA, Mandaliya K, Chohan BH, Kreiss JK, Overbaugh J (2003). Infection with multiple human immunodeficiency virus type I variant is associated with faster disease progression. J Virol 77:12921–12926.CrossRefGoogle Scholar
  35. 35.
    Kaslow RA, Blackwelder WE, Ostrow DG, Yerg D, Palenicek J, Coulson AH, Valdiserri RO (1989). No evidence for a role of alcohol or other psychoactive drugs in accelerating immuno-deficiency in HIV-I positive individuals. JAMA 261:3424–3427.PubMedCrossRefGoogle Scholar
  36. 36.
    Fong IW, Read S, Wainberg M, Chia WK, Major C (1994). Alcoholism and rapid progression to AIDS after seroconversion. Clin Infect Dis 19:337–338.PubMedCrossRefGoogle Scholar
  37. 37.
    Kitahata MM, Gange SJ, Abraham AG, Merriman, B, Saag MS, Justice AG, Hogg RS, Deeks SG, et al. For the NA-ACCORD Investigators (2009). Effect of early versus deferred antiretroviral therapy for HIV on survival. N Engl J Med 360:1815–1826.PubMedCrossRefGoogle Scholar
  38. 38.
    When to Start Consortium (2009). Timing of initiation of antiretroviral therapy in AIDS-free HIV-I infected patients: a collaborative analysis of 18 HIV cohort studies. Lancet 373:1352–1362.CrossRefGoogle Scholar
  39. 39.
    Centers for Disease Control and Prevention (2005). HIV prevalence, unrecognized infection and HIV testing among men who have sex with men – five US cities, June 2004-April 2005. MMWR Morb and Mort Wkly Rep 54:597–601.Google Scholar
  40. 40.
    Centers for Disease Control and Prevention (2006). Sexually transmitted diseases treatment guidelines 2006. MMWR Morb and Mort Wkly Rep 55:1–100.Google Scholar
  41. 41.
    Severe P, Juste MA, Ambroise A, Eliacin L, Marchand C, Appollon S, Edwards A, Bang H, Nicotera J, Godfrey C, Gulick RM, Johnson Jr WD, Pape JW, Fitzgerald DW (2010). Early versus standard antiretroviral therapy for HIV-infected adults in Haiti. N Eng J Med363:259–265.CrossRefGoogle Scholar
  42. 42.
    Jabs DA, Thorne JE (2008) Ophthalmologic Disease. IN (eds) Dolin R, Masur H, Saag M. AIDS Therapy, 3rd Edition, Churchill Livingstone/Elsevier, Philadelphia p1169–1186.Google Scholar
  43. 43.
    Baldassano V, Dunn JP, Feinberg J, Jabs DA (1995). Cytomegalovirus retinitis and low CD4+ T-lymphocyte counts. N Engl J Med 333:670.PubMedCrossRefGoogle Scholar
  44. 44.
    Lalezari JP, Stagg RJ, Kuppermann BD, Holland GN, Kramer F, Ives DV, Youle M, Robinson MR, Drew WL, Jaffe HS (1997). Intravenous cidofovir for peripheral cytomegalovirus retinitis in patients with AIDS. Ann Intern Med 126:257–263.PubMedGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC 2011

Authors and Affiliations

  1. 1.St. Michael’s HospitalUniversity of TorontoTorontoCanada

Personalised recommendations